Cytosorbents (CTSO) Net Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31% |
| Dec 31, 2025 | -57.20% |
| Sep 30, 2025 | -30.43% |
| Jun 30, 2025 | -8.09% |
| Mar 31, 2025 | 15.60% |
| Dec 31, 2024 | -13.89% |
| Sep 30, 2024 | 16.66% |
| Jun 30, 2024 | -3.15% |
| Mar 31, 2024 | -4.51% |
| Dec 31, 2023 | 37.07% |
| Sep 30, 2023 | -25.06% |
| Jun 30, 2023 | -1.12% |
| Mar 31, 2023 | -19.69% |
| Dec 31, 2022 | 24.62% |
| Sep 30, 2022 | -42.81% |
| Jun 30, 2022 | -44.37% |
| Mar 31, 2022 | -42.52% |
| Dec 31, 2021 | -13.66% |
| Sep 30, 2021 | -23.97% |
| Jun 30, 2021 | -9.25% |
| Mar 31, 2021 | -17.81% |
| Dec 31, 2020 | 27.34% |
| Sep 30, 2020 | 21.67% |
| Jun 30, 2020 | -31.94% |
| Mar 31, 2020 | 6.05% |
| Dec 31, 2019 | 6.00% |
| Sep 30, 2019 | -35.66% |
| Jun 30, 2019 | -13.86% |
| Mar 31, 2019 | -38.02% |
| Dec 31, 2018 | -36.81% |
| Sep 30, 2018 | -25.51% |
| Jun 30, 2018 | -32.69% |
| Mar 31, 2018 | -12.86% |
| Dec 31, 2017 | -42.39% |
| Sep 30, 2017 | -25.80% |
| Jun 30, 2017 | -10.62% |
| Mar 31, 2017 | -1.34% |
| Dec 31, 2016 | -32.60% |
| Sep 30, 2016 | -4.82% |
| Jun 30, 2016 | -17.51% |
| Mar 31, 2016 | -8.62% |
| Dec 31, 2015 | -47.77% |
| Sep 30, 2015 | -29.28% |
| Jun 30, 2015 | 32.74% |